Developmental and reproductive toxicity studies on artemisone.

BACKGROUND: In order to justify clinical studies in women of child-bearing age with artemisone, a new artimisinin derivative, studies to assess fertility and early embryonic development in rats, developmental toxicity in rats and rabbits, and peri-post natal development in rats were performed. METHODS AND RESULTS: In the study on fertility and early embryonic development (dose levels 0-5-20-80 mg/kg bw/day), doses inducing clinical and organ toxicity were used. Only in severe toxicity conditions, a reduction of the number of estruses, a prolonged time to insemination, decreased numbers of corpora lutea, implantation sites, and viable fetuses were found. Two developmental toxicity studies were performed in rats (dose levels 0-1-2 mg/kg bw/day) and rabbits (dose levels 0-2.5-5.0-7.5 mg/kg bw/day). It was shown that rats were about 5 times more sensitive than rabbits. In rats, artemisone induced total litter loss (late resorptions) at 2 mg/kg body weight and above with an increased incidence of a common vascular variation and retarded ossification at this dose. In rabbits, maternal toxicity, abortion and a slightly increased incidence of cardiac ventricular septal defects was observed at 7.5 mg/kg body weight. In a pre- and postnatal developmental toxicity study in rats (dose levels 0-1-2-4 mg/kg bw/day), 4 mg/kg body weight artemisone induced clinical symptoms and affected postnatal survival, body weight gain in the F1 pups, and motor activity. CONCLUSIONS: In summary, artemisone was shown to be embryo- and fetotoxic and induced cardiac ventricular septal defects and retarded ossification in dosages where total litter loss and abortions were observed. However, no effect on reproductive and developmental parameters below severe toxic dosages could be observed.

Pharmacokinetic study of dipyrone metabolite 4-MAA in the horse and possible implications for doping control.

The pharmacokinetic behaviour of dipyrone metabolite 4-MAA in serum was determined in seven horses of different breeds after a single intravenous dose administration. A biexponential formula was fitted to the serum concentration vs. time data. The median half-life of the elimination phase (t1/2 beta) was 4.85 h (range 5.04 h), the median volume of distribution (Vd(area)) was 1.85 L/kg (range 3.2 L/kg) and median of total clearance was 4.0 mL/min/kg (range 2.3 mL/min/kg).

[Kinetics of elimination of diazepam after intravenous injection in horses]. / Eliminationskinetik von Diazepam nach intravenöser Applikation beim Pferd.

Diazepam is used in veterinary medicine as sedative and pre-anaesthetic agent. This publication describes the plasma-concentration time curve for diazepam and its metabolite in horses suffering from colic after intravenous application as pre-anaesthetic agent. Elimination half-life (t1/2 beta) after a dose of 0.05-0.08 mg/kg (30-50 mg Diazepam per horse) was 7.5 to 13.2 h. Total clearance (Cltot) between 1.86 and 3.44 ml/min/kg was detected and apparent volume of distribution in steady state (Vdiss) was 1.98 to 2.25 l/kg. Diazepam was still found in serum after 24 h. The metabolite oxazepam could be found in plasma. Its elimination half-life was 14-16.5 hours.

[Natural and synthetic glucocorticoids in the racing horse: a review of the literature]. / Natürliche und synthetische Glukokortikoide beim Sportpferd: eine Literaturübersicht.

This review compromises data about endogenous cortisol and its physiological variations in horses. The influence of synthetic glucocorticoids on the endogenous cortisol concentrations is discussed as well. The second part of the review summarizes detection times of therapeutically used glucocorticoids (dexamethasone, betamethasone, triamcinolone, prednisone, prednisolone, methylprednisolone and hydrocortisone) in the horse and their implication for doping control.

[Doping problems in horse sports--pharmacokinetics of selected antiphlogistics/analgesics relevant to doping]. / Die Dopingproblematik im Pferdesport--Pharmakokinetik ausgewählter dopingrelevanter Antiphlogistika/Analgetika.

Drug treatment of horses which are used in horse-racing is restricted by the regulations of the anti-doping control. Veterinarians and anti-doping control commissions are faced with the problems resulting from the discrepancy between the demand "no drugs in blood/urine of horses at the time of competition" and the need for treatment. The pharmacokinetic data of important antiphlogistics/analgetics (NSAID) for horses given in this article shall facilitate the decision of the veterinarians and commissions whether a horse having been treated with NSAID may participate in a competition or not. Further a new concept of anti-doping regulation of therapeutic substances is presented for discussion.